We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2.
- Authors
Fang, Zhenhao; Peng, Lei; Lucas, Carolina; Lin, Qianqian; Zhou, Liqun; Yang, Luojia; Feng, Yanzhi; Ren, Ping; Renauer, Paul A.; Monteiro, Valter S.; Hahn, Anne M.; Park, Jonathan J.; Zhou, Xiaoyu; Yale SARS-CoV-2 Genomic Surveillance Initiative; Billig, Kendall; Breban, Mallery I.; Castaldi, Christopher; Chaguza, Chrispin; Chen, Nicholas; Ferguson, David
- Abstract
To answer these questions, we characterized the antibody response induced by WT or variant specific LNP-mRNAs to Omicron BA.2 and compared it with immune response to BA.1. Given the BA.2 neutralization titer advantage of variant LNP-mRNA over WT, we went on to profile the antibody response of BA.1 LNP-mRNA to BA.2. Because of shared mutations with BA.1, BA.2 or BA.2.12.1, these variant-specific LNP-mRNAs displayed better performance of inducing neutralizing antibodies than WT LNP-mRNA in booster and non-booster settings. Variant-specific vaccine candidates, or lipid nanoparticle (LNP)-mRNAs, unequivocally exhibited advantage over WT LNP-mRNA in terms of eliciting neutralizing antibody against cognate antigens[5],[6].
- Subjects
SARS-CoV-2 Omicron variant; SARS-CoV-2; VACCINATION; COVID-19; SARS-CoV-2 Delta variant; IMMUNOGLOBULINS
- Publication
Cell Discovery, 2022, Vol 8, Issue 1, p1
- ISSN
2056-5968
- Publication type
Article
- DOI
10.1038/s41421-022-00435-w